新辅助治疗后动脉周围剥离用于腹腔干侵犯的局部晚期胰腺癌
动脉周围剥离组术后胰瘘、腹腔感染和术后肝缺血发生率更低,R0切除率、肿瘤复发和生存无显著差异;新辅助治疗患者较46例直接手术的腹腔干整块切除患者肿瘤病理结局和生存更优。
要点
- 新辅助治疗后腹腔干动脉周围剥离安全可行,需充分影像评估和术中判断。
- 与腹腔干整块切除相比,动脉周围剥离术后胰瘘、腹腔感染和肝缺血更少。
- 两种术式R0切除率、肿瘤复发和生存无显著差异。
核心结论
- 新辅助治疗后对腹腔干侵犯的局部晚期胰腺癌行远端胰腺切除联合腹腔干动脉周围剥离是安全可行的。
主要发现
- 动脉周围剥离组术后胰瘘、腹腔感染和术后肝缺血发生率低于腹腔干整块切除组,R0切除率、术后肿瘤复发和生存无显著差异。
- 46例局部晚期胰腺癌累及腹腔干患者未接受新辅助治疗直接行远端胰腺切除联合腹腔干整块切除,新辅助治疗患者肿瘤病理结局和生存显著更优。
临床怎么用
- 在充分影像评估结合外科医生术中判断的基础上,可对新辅助治疗后腹腔干侵犯的局部晚期胰腺癌行腹腔干动脉周围剥离。
- 该技术推荐在高容量胰腺中心由经验丰富的外科医生实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Modern pancreatic surgery has gradually changed with the introduction of neoadjuvant therapy. For patients with pancreatic cancer involving peripancreatic visceral arteries who have received neoadjuvant therapy, periarterial divestment has gradually gained popularity, which represents an alternative to arterial resection. There is ongoing debate about whether this approach achieves curative tumor resection comparable to that of arterial resection, and the differences in terms of postoperative complications and oncologic outcomes between the 2 surgical procedures. METHODS: We retrospectively analyzed the perioperative and survival outcomes of locally advanced pancreatic cancer patients with celiac axis invasion who underwent distal pancreatectomy in our center from December 2016 to March 2023. RESULTS: Ninety-five patients underwent neoadjuvant therapy as a priority after diagnosis, among whom 42.1% (n = 40) underwent distal pancreatectomy with celiac axis periarterial divestment, whereas 57.9% (n = 55) underwent distal pancreatectomy with en bloc celiac axis resection. Distal pancreatectomy with celiac axis periarterial divestment showed lower rates of postoperative pancreatic fistula, intraabdominal infection, and postoperative hepatic ischemia compared with distal pancreatectomy with en bloc celiac axis resection, with no significant differences in R0 resection rate, postoperative tumor recurrence, and survival. Furthermore, 46 patients diagnosed with locally advanced pancreatic cancer involving the celiac axis underwent upfront surgery of distal pancreatectomy with en bloc celiac axis resection without neoadjuvant therapy. Neoadjuvant therapy patients exhibited significant advantages in terms of tumor pathologic outcomes and survival compared with those undergoing upfront surgery of distal pancreatectomy with en bloc celiac axis resection. CONCLUSION: After neoadjuvant therapy, distal pancreatectomy with celiac axis periarterial divestment in locally advanced pancreatic cancer patients with celiac axis invasion is deemed safe and feasible on the basis of adequate imaging evaluation combined with intraoperative judgment of the surgeons. This technique is recommended to be performed at high-volume pancreatic centers by experienced surgeons.
引用
- Fu Z, Qin J, Zheng K, et al. Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac axis invasion: A safe and effective surgical procedure. Surgery. 2025. PMID: 39793414. doi:10.1016/j.surg.2024.109045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。